Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314184 | 0.85 | PTPN1 (0.38) | ESR1TRPV1THRBPTPN1THRA | |
| SCHEMBL2164006 | 0.82 | FOLH1 (0.41) | FOLH1ESR1TRPV1THRBPTPN1 | |
| SCHEMBL3911299 | 0.82 | FOLH1 (0.41) | FOLH1ESR1TRPV1THRBPTPN1 | |
| SCHEMBL14540741 | 0.82 | FOLH1 (0.41) | FOLH1ESR1TRPV1THRBPTPN1 | |
| SCHEMBL3137725 | 0.82 | FOLH1 (0.41) | FOLH1ESR1TRPV1THRBPTPN1 | |
| SCHEMBL6374059 | 0.81 | THRB (0.47) | FOLH1ESR1TRPV1THRBTHRA | |
| SCHEMBL7275974 | 0.81 | THRB (0.47) | FOLH1ESR1TRPV1THRBTHRA | |
| SCHEMBL18822126 | 0.81 | THRB (0.47) | FOLH1ESR1TRPV1THRBTHRA | |
| SCHEMBL3956951 | 0.79 | FOLH1 (0.45) | FOLH1ESR1TRPV1PTPN1POLB | |
| SCHEMBL15931386 | 0.77 | HDAC1 (0.35) | ESR1ESR2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319096-B2 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders II | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| US-20040220147-A1 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll | KARO BIO AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1387825-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II | KARO BIO AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092550-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II | KARO BIO AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | FOLH1 582/4885ESR1 58/4885TRPV1 265/4885 |
| US-20040220147-A1 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll | TSHR, TRHR, THRA | FOLH1 3352/4885ESR1 635/4885TRPV1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.